Johnson & Johnson vs Novo Nordisk
Johnson & Johnson reported revenue of $94.2 billion in fiscal 2025, and Novo Nordisk DKK 309.1 billion in fiscal 2025, in different currencies. Johnson & Johnson's revenue grew 6.0% in its latest year, and Novo Nordisk's grew 6.4%. Free cash flow was $19.7 billion at Johnson & Johnson and DKK 59.0 billion at Novo Nordisk. Their fiscal years end in different months (December 28 and December 31), so the periods don't line up exactly.
Side by side
| Johnson & Johnson | Novo Nordisk | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 28, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $94.2B | DKK 309.1B |
| Revenue growth | 6.0% | 6.4% |
| Revenue growth a year, last 5 years | 2.7% | 19.5% |
| Gross margin | 67.9% | 81.0% |
| Operating margin | — | 41.3% |
| Net margin | 28.5% | 33.1% |
| Free cash flow | $19.7B | DKK 59.0B |
| Free cash flow margin | 20.9% | 19.1% |
| Return on capital | 28.6% | 36.1% |
| Net debt to EBITDA | 0.7x | 0.8x |
| Dividends and buybacks | $18.3B | DKK 53.2B |
| Change in diluted share count | 0.0% | −0.3% |
| Last close | $266.30 | $39.13 |
| P/E at the last close | 40.4× | — |
| Insider trades, last 12 months | bought $257,688, sold $150.7 million | — |
| Piotroski F-score | 4 of 9 | 6 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
In each company's own currency, fiscal years
Johnson & JohnsonNovo Nordisk
Operating margin
Percent of revenue
Johnson & JohnsonNovo Nordisk
Free cash flow
In each company's own currency. Cash from operations minus capital expenditure.
Johnson & JohnsonNovo Nordisk
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Johnson & Johnson and Novo Nordisk pages.